No effect of the Trp64Arg variant of the beta3-adrenergic receptor gene on weight loss by diet and exercise intervention among Japanese adults.

Controversy remains as to whether the presence of the tryptophan-to-arginine (Trp64Arg) variant of the beta(3)-adrenergic receptor gene impedes the magnitude of body weight loss by diet and exercise intervention. The objectives of the present study were to compare the changes in body weight between carriers and noncarriers of the Trp64Arg variant before and after 6 months of diet and exercise interventions for weight loss. A total of 37 middle-aged Japanese individuals (12 carriers and 25 noncarriers of the Trp64Arg variant) participated in the study. There were no significant differences in body weight between the 2 groups at the baseline. There were significant reductions in body weight both in carriers and noncarriers, but no significant differences between the 2 groups with respect to changes in these variables. The weight changes were -2.52 kg (95% confidence interval [CI], -3.56 to -1.48) among carriers and -1.89 kg (95% CI, -2.65 to -1.13) among noncarriers, and the change in the variant carrier group minus the change in the variant noncarrier group was -0.47 (95% CI, -1.97 to 1.02). These results suggest that the presence of the Trp64Arg variant of the beta(3)-adrenergic receptor gene may not play a major role as a hindrance to weight reduction.

RCT Entities:   Population Interventions Outcomes